This study focuses on chronic active antibody-mediated rejection, a condition that can occur in people who have received a kidney transplant. This type of rejection happens when the body’s immune system creates antibodies that attack the transplanted kidney, which can lead to decreased kidney function over time. The study will test a medication called tocilizumab (RoActemra), which is given as an injection under the skin.
The purpose of the study is to determine if adding tocilizumab to standard care treatment works better than standard care alone in preserving kidney function in transplant recipients who have this type of rejection. The medication will be given as a 162 mg injection under the skin for a period of 24 months.
During the study, participants will have their kidney function monitored through blood tests that measure how well their kidneys are filtering waste products from their blood. They will also have kidney tissue samples taken and undergo other medical tests to check their overall health and the condition of their transplanted kidney. The total duration of monitoring will last for 36 months, with regular check-ups to assess the kidney’s function and the participant’s general health.
Spain 
Sweden 
